This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J (JNJ) to Begin Q2 Earnings Season for Drug, Biotech Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex. In the MedTech segment, recovery in surgical procedures and new product launches are likely to have pushed sales growth.
Eli Lilly (LLY) to Buy Versanis, Strengthen Obesity Portfolio
by Zacks Equity Research
For the purchase of Versanis, Lilly (LLY) agrees to pay up to $1.93 billion in cash.
Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed at $154.75 in the latest trading session, marking a +1.64% move from the prior day.
Novo Nordisk (NVO) Falls on EMA Safety Review of Obesity Drugs
by Zacks Equity Research
Novo Nordisk's (NVO) important diabetes care and obesity drugs are under review by the EMA's safety committee for the risk of suicidal behavior with its use. The stock falls 3%.
Novo Nordisk (NVO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed at $158.32 in the latest trading session, marking a -1.05% move from the prior day.
Can Eli Lilly's (LLY) Continue its Ride on Obesity Drug Wave?
by Zacks Equity Research
Lilly (LLY) continues to raise the bar on obesity drugs as latest data show that participants treated with these experimental drugs achieved mean weight reduction of up to 24%.
Novo Nordisk (NVO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $157.03, marking a +0.15% move from the previous day.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer (PFE) Gets FDA Nod for Growth Hormone Deficiency Drug
by Zacks Equity Research
The FDA approves Pfizer (PFE) and OPKO Health's (OPK) Ngenla to treat growth hormone deficiency in pediatric patients. The drug's commercial launch is expected this August.
The Zacks Analyst Blog Highlights Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing
by Zacks Equity Research
Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing are included in this Analyst Blog.
Top Stock Reports for Novo Nordisk, Home Depot & Walt Disney
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), The Home Depot, Inc. (HD) and The Walt Disney Company (DIS).
Pfizer (PFE) Stock Down on Halting Development of Obesity Drug
by Zacks Equity Research
Shares of Pfizer's (PFE) fell 3.7% on Monday after management's decision to terminate the development of an experimental obesity pill following concerns over liver safety.
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data
by Zacks Equity Research
Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.
Novo Nordisk (NVO) Stock Moves -0.59%: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $159.07, moving -0.59% from the previous trading session.
Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $159.07, marking a +0.91% move from the previous day.
Novartis (NVS) Sandoz Presents Standalone Growth Strategy
by Zacks Equity Research
Novartis generic arm, Sandoz, which will be spun off, expects strong growth as a standalone company, driven by increasing contribution from biosimilars.
FDA Accepts Vertex (VRTX), CRISPR's BLA Filings for Exa-Cel
by Zacks Equity Research
The FDA grants priority review to Vertex (VRTX)/CRISPR's (CRSP) filings for exa-cel in SCD, with a final decision expected in December.
3 Reasons Why Growth Investors Shouldn't Overlook Novo Nordisk (NVO)
by Zacks Equity Research
Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review
by Zacks Equity Research
FDA accepts Merck's (MRK) supplemental biologics license application for Keytruda plus chemotherapy for the treatment of patients with first-line advanced or metastatic biliary tract cancer.
Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $159.45, moving +1.22% from the previous trading session.
FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8%
by Zacks Equity Research
FibroGen???s (FGEN) phase III study, evaluating pamrevlumab as a combination therapy in certain DMD patients, fails to meet its primary endpoint.
Intercept (ICPT) Announces Positive Data From PBC Study
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple biomarkers in primary biliary cholangitis.
Merck (MRK) Sues US Government to Halt Drug Price Negotiations
by Zacks Equity Research
Merck (MRK) files a lawsuit against claiming that the federal government is violating the Constitution by forcing drugmakers to negotiate prices at below market rates.
Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA
by Zacks Equity Research
Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.